You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Janssen Biotech Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Janssen Biotech
International Patents:834
US Patents:35
Tradenames:5
Ingredients:5
NDAs:5
Patent Litigation for Janssen Biotech: See patent lawsuits for Janssen Biotech

Drugs and US Patents for Janssen Biotech

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Janssen Biotech AKEEGA abiraterone acetate; niraparib tosylate TABLET;ORAL 216793-001 Aug 11, 2023 RX Yes No 11,091,459 ⤷  Subscribe Y Y ⤷  Subscribe
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-003 Apr 12, 2019 RX Yes Yes 9,902,714 ⤷  Subscribe Y ⤷  Subscribe
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No 9,902,714 ⤷  Subscribe Y ⤷  Subscribe
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-002 Apr 12, 2019 RX Yes No 11,077,106 ⤷  Subscribe ⤷  Subscribe
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No 10,898,482 ⤷  Subscribe Y ⤷  Subscribe
Janssen Biotech LAZCLUZE lazertinib mesylate TABLET;ORAL 219008-001 Aug 19, 2024 RX Yes No 9,593,098 ⤷  Subscribe Y Y ⤷  Subscribe
Janssen Biotech LAZCLUZE lazertinib mesylate TABLET;ORAL 219008-001 Aug 19, 2024 RX Yes No 11,453,656 ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries
Paragraph IV (Patent) Challenges for JANSSEN BIOTECH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 500 mg ➤ Subscribe 2017-08-23
➤ Subscribe Tablets 250 mg ➤ Subscribe 2015-04-28

International Patents for Janssen Biotech Drugs

CountryPatent NumberEstimated Expiration
Australia 2004294790 ⤷  Subscribe
Austria 508118 ⤷  Subscribe
Canada 3059543 ⤷  Subscribe
Eurasian Patent Organization 032145 ⤷  Subscribe
Eurasian Patent Organization 201992501 ⤷  Subscribe
Mexico 2021004110 ⤷  Subscribe
Portugal 3533792 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration
Showing 1 to 7 of 7 entries

Supplementary Protection Certificates for Janssen Biotech Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
3533792 122021000067 Germany ⤷  Subscribe PRODUCT NAME: APALUTAMID; REGISTRATION NO/DATE: EU/1/18/1342 20190114
1633724 13/2015 Austria ⤷  Subscribe PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
2240466 132018000000301 Italy ⤷  Subscribe PRODUCT NAME: NIRAPARIB TOSILATO O UN SUO IDRATO, IN PARTICOLARE IL TOSILATO MONOIDRATO(ZEJULA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1235, 20171120
2368550 C 2019 029 Romania ⤷  Subscribe PRODUCT NAME: APALUTAMIDA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1342; DATE OF NATIONAL AUTHORISATION: 20190114; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1342; DATE OF FIRST AUTHORISATION IN EEA: 20190114
2109608 C201830023 Spain ⤷  Subscribe PRODUCT NAME: NIRAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1235; DATE OF AUTHORISATION: 20171116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1235; DATE OF FIRST AUTHORISATION IN EEA: 20171116
2368550 CA 2019 00029 Denmark ⤷  Subscribe PRODUCT NAME: APALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1342 20190116
2368550 CR 2019 00029 Denmark ⤷  Subscribe PRODUCT NAME: APALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1342 20190116
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 7 of 7 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.